This HTML5 document contains 182 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q46414306
rdf:type
wikibase:Item
schema:description
tudományos cikk videnskabelig artikel научная статья 2008年学术文章 wissenschaftlicher Artikel vitskapeleg artikkel ശാസ്ത്രപ്രബന്ധം​ teaduslik artikkel наукова стаття, опублікована в серпні 2008 article científic scienca artikolo 2008年學術文章 artículo científico publicado en 2008 научни чланак artikel ilmiah wetenschappelijk artikel bài báo khoa học scientific article published in August 2008 2008年学术文章 სამეცნიერო სტატია tieteellinen artikkeli 2008年學術文章 scientific article published in August 2008 artigo científico article scientifique επιστημονικό άρθρο naučni članak научна статия article scientific مقالة علمية نشرت في أغسطس 2008 2008年学术文章 artikulong pang-agham bilimsel makale vědecký článek 2008年學術文章 artykuł naukowy vetenskaplig artikel научни чланак 2008年学术文章 scientific article published in August 2008 บทความทางวิทยาศาสตร์ 2008 nî lūn-bûn artigo científico artículu científicu 2008年学术文章 আগস্ট ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ articolo scientifico 2008年學術文章 мақолаи илмӣ 2008年学术文章 artikull shkencor articol științific vitenskapelig artikkel מאמר מדעי 2008年の論文 artigo científico vedecký článok 2008년 논문 2008年學術文章
p:P577
wds:Q46414306-28B9BA4C-828F-475A-8206-0FA32B0943BE
wdt:P577
2008-08-01T00:00:00Z
p:P407
wds:Q46414306-327BAA0E-2470-49E5-8C00-62BF53C67427
wdt:P407
wd:Q1860
p:P2860
wds:Q46414306-DF26D8B2-EAF8-431F-B0A4-2B263BC01C46 wds:Q46414306-E3807C62-02DD-4261-8E4A-87A724CE654B wds:Q46414306-EC0C2656-210D-4BD0-B4CB-D3136F7264C2 wds:Q46414306-CAE1122D-A9C4-49D8-83D3-A4496F700742 wds:Q46414306-CED4721C-74AD-449D-BFB5-0D1998A9BE52 wds:Q46414306-B9842879-1A36-4291-960C-8B1940F24771 wds:Q46414306-BAB0B6D4-4051-490A-B30A-3B6CCCB23999 wds:Q46414306-A5D261AB-123B-47EE-8116-3551709C50B9 wds:Q46414306-899C4676-C4C7-47FA-A12E-1ABBEFA00622 wds:Q46414306-9435BF3F-C496-4288-B7A7-AB335FD82682 wds:Q46414306-83D6A197-0DC2-484F-BF29-1CED9F64BF89 wds:Q46414306-5E45514B-83E9-4891-9C45-56FB499F8A41 wds:Q46414306-65BBFF3D-6771-4E8D-8D86-8A568A3300B1 wds:Q46414306-4E5E9CB7-044B-4BD5-AF6D-288F05D8AB8F wds:Q46414306-5CA16D80-A2CE-44F0-B7D1-74A484C52678 wds:Q46414306-3C4319DE-3163-4C55-97AF-BC20B0AE9EB5 wds:Q46414306-45B6B9E5-36E0-402F-9E13-1E5732025F4E wds:Q46414306-2D0917FF-03F2-45EE-8E40-62CCFD71CD4B wds:Q46414306-32B6F2CA-5CFC-4831-8DCA-A9BBCCA27B7E wds:Q46414306-2B814FE7-8B63-491E-803F-DD703ECA7291 wds:Q46414306-2CBAD120-0B3A-4A01-80AB-7CF3D7241E6F wds:Q46414306-21D04A32-CFD6-428F-91C5-2D9508B1E977 wds:Q46414306-26987DFF-F8E5-417D-9BB0-DAB7C49F5672 wds:Q46414306-0B5CDC35-C779-4C94-996D-DBBC0739CD5E wds:Q46414306-0DC3F4FC-37A2-401B-BD13-DF293400BCC9
wdt:P2860
wd:Q36653838 wd:Q50105738 wd:Q51943315 wd:Q43840888 wd:Q57181081 wd:Q57117642 wd:Q39563727 wd:Q46973541 wd:Q44662157 wd:Q28256092 wd:Q46851728 wd:Q34631629 wd:Q46435678 wd:Q44951046 wd:Q36304804 wd:Q46562126 wd:Q36765802 wd:Q28344472 wd:Q35913181 wd:Q41752733 wd:Q61790672 wd:Q30482995 wd:Q36831639 wd:Q46492574 wd:Q33933318
p:P2093
wds:Q46414306-04EDB91F-06F1-4D27-ABA9-644671008C50 wds:Q46414306-28F55DA4-D14C-467F-B45D-D08788FD4BD5 wds:Q46414306-16873AD7-99C5-4379-997B-24806F0060F4 wds:Q46414306-17C75076-8BDC-47C8-BC62-A67BB27FC460 wds:Q46414306-28AB35CB-4BD3-4FB3-80BF-1041ACDAC892 wds:Q46414306-7013F7F2-CAE8-4807-8405-EB83A373718A wds:Q46414306-395CCE80-62BC-47F9-9D73-C75B97F92A87 wds:Q46414306-D3C583F3-0712-43F8-8D90-816F7510BB80 wds:Q46414306-86410E7F-EF9C-466A-9BBD-2381652B8F6B wds:Q46414306-B578BF0D-FBDB-4705-9B8B-A57F075D670F wds:Q46414306-DC2EC93F-48B4-4726-845A-35C620FB3AE1 wds:Q46414306-FD3F3458-20DC-4842-AFCA-C1F22C308AC5
wdt:P2093
Jaime Andrade-Villanueva CASTLE Study Team Graeme Moyle Rong Yang Alexandra Thiry Marco Mancini Neal David Ploenchan Chetchotisakd Lisa Percival Juan Echevarria Jorge Corral Donnie McGrath
rdfs:label
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
skos:prefLabel
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
schema:name
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
p:P50
wds:Q46414306-D32CFF02-83A7-46F9-AE88-3D3FD369D130
wdt:P50
wd:Q108298727
p:P1476
wds:Q46414306-475D680D-1CCA-4102-8553-A4E9252C318D
wdt:P1476
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
p:P304
wds:Q46414306-B132DD90-3C0A-4730-B335-C79F2F754646
wdt:P304
646-655
p:P31
wds:Q46414306-44E6D9ED-4C0F-4E93-9F20-3D386026910D
wdt:P31
wd:Q13442814
p:P921
wds:Q46414306-00A2C2AC-7509-45EB-AAF0-89D8C5A94D90 wds:Q46414306-4C27D031-2E28-442C-A786-E942EAC1577A wds:Q46414306-672906B8-867C-402A-80A3-572C20BCFFBB wds:Q46414306-6C73A732-75A9-4D28-ACEB-BE3D491ECE81 wds:Q46414306-2146148C-21C9-4A83-9038-43846E552EB8 wds:Q46414306-8AF07C38-45EF-433D-870C-452F1965717E wds:Q46414306-9C546FCF-2594-482F-ADD1-0187D971ACF0 wds:Q46414306-C215CBA7-1A50-4AD5-9C9B-E3C441FEE6DC
wdt:P921
wd:Q155954 wd:Q39053473 wd:Q423467 wd:Q422618 wd:Q422604 wd:Q422585 wd:Q3836750 wd:Q181600
p:P698
wds:Q46414306-81C9EBC8-9698-4AFB-86DF-7C52D03CD30B
wdtn:P698
n9:18722869
wdt:P698
18722869
p:P1433
wds:Q46414306-EDF8F4DF-6403-4689-B1CD-76980BE091B6
wdt:P1433
wd:Q939416
p:P433
wds:Q46414306-7C4CA506-81F2-4EF8-BAB0-2B5E0E596215
p:P478
wds:Q46414306-F658F061-E3EF-45E9-9129-F6C610C4BA04
wdt:P433
9639
wdt:P478
372
p:P1104
wds:Q46414306-C3C7D1F4-FFA5-4E8F-828E-12D79BB73BA5
wdt:P1104
10
p:P356
wds:Q46414306-31A7ACD6-205F-47DE-9683-158E4374E2E9
wdtn:P356
n11:S0140-6736(08)61081-8
wdt:P356
10.1016/S0140-6736(08)61081-8